Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Day: January 25, 2023
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Newsight Imaging to Present at Drive TLV Smart Mobility Events in Silicon Valley and Atlanta
NESS ZIONA, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Newsight Imaging Ltd. (“Newsight”), a leading semiconductor innovator developing proprietary 3D...
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue ToxicitySOUTH SAN FRANCISCO, Calif., Jan....
TOMI to Attend Three Leading Pharmaceutical Conferences in the First Quarter of 2023
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company...
SciSparc Announces Corporate Restructuring plan
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV,...
Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for...
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr....
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company...
Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses
The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant.NEW YORK, Jan. 25, 2023 (GLOBE...
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
First Immunosynthen ADC product candidate enters the clinicCAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN),...
Grace Breeding Study Results of its Proprietary Environment- Friendly Bio-Fertilizer (“NFT”) Show Superior Growth Results in Brazilian Corn, Outperforming Standard Nitrogen Fertilizers While Reducing Carbon Emissions
Final study results show Grace Breeding’s NFT, an alternative to reduce urea, was superior or equal to standard nitrogen-based urea...
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
Topline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25,...
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in...
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to...
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical...